Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
- Conditions
- Gastroesophageal AdenocarcinomaGastric Adenocarcinoma
- Registration Number
- NCT00073502
- Lead Sponsor
- OSI Pharmaceuticals
- Brief Summary
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 43
Documented locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction No prior chemotherapy for locally advanced or metastatic disease Adequate baseline bone marrow, hepatic and renal function Age >= 18 years At least one target lesion
Active or uncontrolled infections or other serious illnesses or other medical conditions (eg, hepatitis, HIV, chronic alcohol abuse) Symptomatic brain metastases which are not stable
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
University of Pennsylvania Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
University of Utah, Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
Dept Internal Medicine Gastrointestinal Oncology Unit
🇧🇪B-3000 Leuven, Belgium
Bristol Haematology & Oncology Centre
🇬🇧Bristol, Avon, United Kingdom
ICRF Medical Oncology Unit
🇬🇧Oxford, Oxfordshire, United Kingdom
Deanesly Centre
🇬🇧Wolverhampton, West Midlands, United Kingdom
NICCTU, East Podium, C-Floor
🇬🇧Belfast, United Kingdom
Beatson Oncology Centre
🇬🇧Glasgow, United Kingdom
Cookridge Hospital
🇬🇧Leeds, United Kingdom
Scroll for more (1 remaining)University of Pennsylvania Cancer Center🇺🇸Philadelphia, Pennsylvania, United States